Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 12, 2016, details the completion of Jazz Pharmaceuticals Plc's acquisition of Celator Pharmaceuticals, Inc. The transaction was executed via a cash tender offer followed by a merger under Section 251(h) of the Delaware General Corporation Law.
Key Financial Metrics and Transaction Details
- Acquisition Price: $30.25 per share in cash.
- Tender Offer Results: 36,516,173 shares validly tendered (81.13% of outstanding shares).
- Guaranteed Delivery: Notices delivered for an additional 2,016,237 shares (4.48% of outstanding shares).
- Financing: Jazz utilized $1.0 billion in loans from a new Revolving Credit Facility and cash on hand to fund the purchase of tendered shares.
- Debt Structure:
- Revolving Credit Facility: $1.25 billion (increased from $750 million).
- Term Loan Facility: $750 million (approximately $722 million outstanding).
- Maturity Date: Extended to July 12, 2021.
Material Changes
The primary material change is the full acquisition of Celator Pharmaceuticals, which is now an indirect wholly-owned subsidiary of Jazz. Additionally, Jazz amended its existing credit agreement to increase borrowing capacity and extend the maturity date to support the acquisition and future corporate development activities.
Outlook, Risks, and Contingencies
Management Commentary: The company expects to use proceeds from future loans under the Revolving Credit Facility for general corporate purposes, including corporate development activities.
Risks and Covenants: The Amended Credit Agreement includes financial covenants requiring the company not to exceed a maximum secured net leverage ratio or fall below a cash interest coverage ratio. Events of default include failure to make payments, insolvency, bankruptcy, and change of control. Obligations are secured by a perfected security interest in substantially all tangible and intangible assets of the Loan Parties.
Unusual Items: The filing notes that financial statements of the business acquired and pro forma financial information will be filed within 71 days of this report.
Investor Verification Checklist
- Verify the final total consideration paid for Celator shares, including the impact of guaranteed delivery notices.
- Review the upcoming 10-Q filing for the Amended Credit Agreement text and specific financial covenant thresholds.
- Monitor the filing of pro forma financial information to assess the combined entity's leverage and liquidity position.
- Confirm the integration timeline and any potential synergies or cost impacts from the Celator acquisition.